Autoimmune Diseases of the Nervous System

The grounding supports an autoimmune aetiology driven by immune responses against nervous system autoantigens. In some disorders, pathogenic autoantibodies are implicated, while in others T-cell-dominated inflammation is described. The supplied material also notes distinct antigenic targets, including node-of-Ranvier antigens in autoimmune nodopathies and intracellular antigens in some autoimmune encephalitides.

Disease mechanisms include both cellular and humoral immune injury to nervous tissue. The literature describes inflammatory pathways involving innate and adaptive immunity, cytokines, blood-brain barrier disruption, neuronal loss, astrogliosis, microglial nodules, and in some settings enhanced neuronal excitability and impaired cell survival. Autoantibody subclass and epitope specificity are highlighted as important determinants of pathology and therapeutic implications.

The supplied grounding identifies autoantigen-specific biomarkers for patients at high risk of autoimmune neurological diseases, but it does not provide broader epidemiologic risk factors. It also notes that some autoimmune neurological diseases are paraneoplastic or idiopathic, which describes disease context rather than a general risk factor. No additional risk factors are supported by the grounding.

Treatment is described at the level of immunotherapy, especially disease-modifying therapies and B-cell-targeting agents. The grounding specifically mentions monoclonal antibodies such as anti-CD20 therapies and inebilizumab, and notes that CAR T-cell therapy is being explored for antibody-mediated central nervous system disorders. It also indicates that treatment approaches vary by disease subtype and autoantibody class, but does not support more specific regimen details.